BriaCell Therapeutics Corp.
BCT.TO
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.42% | 3.20% | 1.76% | -2.76% | -21.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.17% | 12.51% | 1.32% | -18.38% | -30.76% |
| Operating Income | -31.17% | -12.51% | -1.32% | 18.38% | 30.76% |
| Income Before Tax | -57.71% | -155.59% | -73.48% | -438.49% | -221.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.71% | -155.59% | -73.48% | -438.49% | -221.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 46.09% | 148.18% | 139.28% | 74.30% | 95.36% |
| Net Income | -57.84% | -155.67% | -72.99% | -449.14% | -224.13% |
| EBIT | -31.17% | -12.51% | -1.32% | 18.38% | 30.76% |
| EBITDA | -31.53% | -12.65% | -1.32% | 18.49% | 31.16% |
| EPS Basic | 79.24% | 34.92% | 59.85% | -86.50% | -46.54% |
| Normalized Basic EPS | 79.09% | 34.54% | 59.83% | -89.05% | -47.16% |
| EPS Diluted | 79.22% | 34.91% | 59.84% | 53.24% | 55.96% |
| Normalized Diluted EPS | 79.09% | 34.54% | 59.83% | -79.25% | -41.20% |
| Average Basic Shares Outstanding | 1,263.32% | 781.69% | 567.73% | 287.01% | 120.79% |
| Average Diluted Shares Outstanding | 1,263.32% | 781.69% | 567.73% | 282.90% | 118.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |